Community hospital based phase II (prospective randomized) study to evaluate the toxicity of
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly
diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian
tube, and primary peritoneal cancer.